Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials
JD Sackner-Bernstein, M Kowalski, M Fox, K Aaronson - Jama, 2005 - jamanetwork.com
ContextNesiritide improves symptoms in patients with acutely decompensated heart failure
compared with placebo and appears to be safer than dobutamine. Its short-term safety
relative to standard diuretic and vasodilator therapies is less clear. ObjectiveTo investigate
the safety of nesiritide relative to noninotrope-based control therapies, primarily consisting of
diuretics or vasodilators. Data SourcesPrimary reports of completed clinical trials as of
December 2004 were obtained from the US Food and Drug Administration (FDA), the study …
compared with placebo and appears to be safer than dobutamine. Its short-term safety
relative to standard diuretic and vasodilator therapies is less clear. ObjectiveTo investigate
the safety of nesiritide relative to noninotrope-based control therapies, primarily consisting of
diuretics or vasodilators. Data SourcesPrimary reports of completed clinical trials as of
December 2004 were obtained from the US Food and Drug Administration (FDA), the study …